



## Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025

AUSTIN, Texas, April 30, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at The Citizens Life Sciences Conference 2025 on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.



A live webcast of the event can be accessed at <https://ir.reintx.com/events-presentations>. A replay of the webcast will be available for 90 days following the presentation.

### About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. For more information, please visit the company's website at [reintx.com](https://reintx.com), or follow them on [LinkedIn](#) and [X](#).

### Rein Investor Relations & Media Contact:

Argot Partners

[rein@argotpartners.com](mailto:rein@argotpartners.com)

212-600-1902

View original content to download multimedia: <https://www.prnewswire.com/news-releases/rein-therapeutics-to-present-at-the-citizens-life-sciences-conference-2025-302443270.html>

SOURCE Rein Therapeutics, Inc.